CN106459165B - 密封蛋白-6特异性免疫受体和t细胞表位 - Google Patents

密封蛋白-6特异性免疫受体和t细胞表位 Download PDF

Info

Publication number
CN106459165B
CN106459165B CN201580017607.3A CN201580017607A CN106459165B CN 106459165 B CN106459165 B CN 106459165B CN 201580017607 A CN201580017607 A CN 201580017607A CN 106459165 B CN106459165 B CN 106459165B
Authority
CN
China
Prior art keywords
cells
cell
cldn6
peptide
cell receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580017607.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459165A (zh
Inventor
尤格·萨因
欧兹兰·图勒茨
皮特拉·西蒙
塔纳·奥莫科科
霍尔戈尔·霍夫
拉尔夫-霍尔戈尔·沃斯
安德里亚·布莱特克洛伊茨
凯思琳·霍博姆
卡罗利娜·安娜·姆罗兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Byrne Technology Cell & Gene Therapy Co ltd
Ganimead Pharmaceutical Co ltd
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Astellas Pharma Inc
Original Assignee
Byrne Technology Cell & Gene Therapy Co ltd
Ganymed Pharmaceuticals GmbH
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52745896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106459165(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byrne Technology Cell & Gene Therapy Co ltd, Ganymed Pharmaceuticals GmbH, Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH filed Critical Byrne Technology Cell & Gene Therapy Co ltd
Priority to CN202110279207.7A priority Critical patent/CN113150110A/zh
Priority to CN202110278993.9A priority patent/CN113150109A/zh
Publication of CN106459165A publication Critical patent/CN106459165A/zh
Application granted granted Critical
Publication of CN106459165B publication Critical patent/CN106459165B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
CN201580017607.3A 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位 Active CN106459165B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110279207.7A CN113150110A (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位
CN202110278993.9A CN113150109A (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2014/000868 2014-04-01
EP2014000868 2014-04-01
EP2014072864 2014-10-24
EPPCT/EP2014/072864 2014-10-24
PCT/EP2015/056899 WO2015150327A1 (en) 2014-04-01 2015-03-30 Claudin-6-specific immunoreceptors and t cell epitopes

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110278993.9A Division CN113150109A (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位
CN202110279207.7A Division CN113150110A (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位

Publications (2)

Publication Number Publication Date
CN106459165A CN106459165A (zh) 2017-02-22
CN106459165B true CN106459165B (zh) 2021-04-20

Family

ID=52745896

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110278993.9A Pending CN113150109A (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位
CN201580017607.3A Active CN106459165B (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位
CN202110279207.7A Pending CN113150110A (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110278993.9A Pending CN113150109A (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110279207.7A Pending CN113150110A (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位

Country Status (21)

Country Link
US (3) US10370423B2 (enExample)
EP (3) EP3514172B1 (enExample)
JP (3) JP6726656B2 (enExample)
CN (3) CN113150109A (enExample)
AU (3) AU2015239683B2 (enExample)
CA (1) CA2942459C (enExample)
CY (1) CY1121539T1 (enExample)
DK (3) DK3126381T4 (enExample)
ES (3) ES2982838T3 (enExample)
FI (1) FI3708579T3 (enExample)
HR (2) HRP20240926T1 (enExample)
HU (3) HUE044515T2 (enExample)
LT (2) LT3126381T (enExample)
ME (1) ME03407B (enExample)
MX (1) MX376026B (enExample)
PL (3) PL3514172T3 (enExample)
PT (3) PT3126381T (enExample)
RS (2) RS65784B1 (enExample)
SI (3) SI3126381T2 (enExample)
SM (1) SMT201900262T1 (enExample)
WO (1) WO2015150327A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202110692WA (en) * 2009-11-11 2021-12-30 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (cldn6)
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
US10053511B2 (en) 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
JP6666342B2 (ja) 2014-11-14 2020-03-13 アメリカ合衆国 抗サイログロブリンｔ細胞レセプター
CN106146666B (zh) * 2015-03-26 2019-09-06 科济生物医药（上海）有限公司 靶向cldn6的免疫效应细胞及其制备方法和应用
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
WO2016180468A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
IL303905A (en) 2015-05-18 2023-08-01 Tcr2 Therapeutics Inc Compositions and methods for TCR programming using fusion proteins
CN107849148B (zh) 2015-05-21 2023-09-19 哈普恩治疗公司 三特异性结合蛋白质及使用方法
GB201607534D0 (en) * 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CN114028549A (zh) 2016-02-19 2022-02-11 伊玛提克斯生物技术有限公司 用于nhl和其他癌症免疫治疗的新型肽和肽组合物
CN109641012A (zh) 2016-06-07 2019-04-16 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 与bcma结合的嵌合抗原受体和car-t细胞
KR20240113990A (ko) 2016-06-27 2024-07-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
MX2018015853A (es) 2016-07-14 2019-08-21 Genmab As Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
ES2875959T3 (es) * 2016-10-07 2021-11-11 Tcr2 Therapeutics Inc Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
US12269859B2 (en) 2016-12-02 2025-04-08 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
EP3595708A4 (en) * 2017-03-15 2020-12-16 Fred Hutchinson Cancer Research Center HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES
SG11201908659RA (en) * 2017-03-27 2019-10-30 Noile Immune Biotech Inc Chimeric antigen receptor
AU2018309339C1 (en) 2017-08-04 2025-08-21 BioNTech SE Binding agents binding to PD-L1 and CD137 and use thereof
JP7599332B2 (ja) * 2017-09-18 2024-12-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６抗体及びがんを治療するための方法
JP7273716B2 (ja) 2017-09-29 2023-05-15 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN120983617A (zh) 2018-11-06 2025-11-21 健玛保 抗体配制剂
WO2020097530A2 (en) * 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center Immunotherapy targeting mesothelin
EP4198057A1 (en) * 2018-12-05 2023-06-21 F. Hoffmann-La Roche AG Diagnostic methods and compositions for cancer immunotherapy
SI3920939T1 (sl) * 2019-02-08 2025-03-31 Biontech Cell & Gene Therapies Gmbh Celice, modificirane s himernim antigenskim receptorjem, za zdravljenje cldn6-izražajočih rakov
CA3132072A1 (en) * 2019-03-01 2020-09-10 Gritstone Bio, Inc. Selection of t cell receptors
ES3017207T3 (en) 2019-03-20 2025-05-12 Univ California Claudin-6 antibodies and drug conjugates
WO2021129927A1 (en) * 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
EP4100059A1 (en) 2020-02-04 2022-12-14 Genmab A/S Antibodies for use in therapy
KR20230107281A (ko) 2020-11-11 2023-07-14 비온테크 에스이 프로그램된 사멸-1 단백질에 대한 모노클로날 항체 및 의약에서의 용도
US20240216427A1 (en) * 2020-12-30 2024-07-04 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1)
TW202315891A (zh) 2021-06-21 2023-04-16 丹麥商珍美寶股份有限公司 結合劑給藥排程
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
EP4395823A4 (en) * 2021-09-03 2025-07-16 Novarock Biotherapeutics Ltd BISPECIFIC BINDING PROTEINS THAT BIND TO CD137 AND A TUMOR-ASSOCIATED ANTIGEN
EP4412714A1 (en) 2021-10-06 2024-08-14 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
IL311771A (en) 2021-10-06 2024-05-01 BioNTech SE Multispecific binding agents against pd-l1 and cd137 in combination
CA3234897A1 (en) * 2021-10-14 2023-04-20 Kunle Odunsi Compositions and methods for use of recombinant t cell receptors against claudin 6
EP4522654A1 (en) 2022-05-12 2025-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
EP4522657A1 (en) 2022-05-12 2025-03-19 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
CN119365215A (zh) 2022-05-12 2025-01-24 健玛保 在组合疗法中能够结合cd27的结合剂
CN115232207B (zh) * 2022-05-19 2023-06-13 河南大学 抗体-溶菌素（SM-ScFv-Fc-Ly）在治疗变形链球菌感染中的应用
WO2024165057A1 (en) * 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies and antibody-drug conjugates targeting claudin 6
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy
WO2025184170A1 (en) 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment
CN118812714B (zh) * 2024-08-21 2025-05-27 广州百吉生物制药有限公司 一种紧密连接蛋白抗体b3及其应用
CN119320451B (zh) * 2024-08-21 2025-05-16 百吉生物医药(广州)股份有限公司 一种紧密连接蛋白抗体d03及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138576A1 (en) * 2007-03-16 2009-12-30 Kyowa Hakko Kirin Co., Ltd. Anti-claudin-4 antibody
CN102325885A (zh) * 2009-02-20 2012-01-18 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
JP2009508517A (ja) * 2005-09-22 2009-03-05 コーエン，イルン，アール Ｔ細胞受容体定常ドメインの免疫原性断片及びそれに由来するペプチド
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CA2711557A1 (en) * 2008-01-11 2009-07-16 The University Of Tokyo Anti-cldn6 antibody
SG10202110692WA (en) * 2009-11-11 2021-12-30 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (cldn6)
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
EP2547695B1 (en) * 2010-03-16 2018-05-09 Biontech Protein Therapeutics GmbH Tumor vaccination involving a humoral immune response against self-protein cldn18.2
CN102971421A (zh) * 2010-04-13 2013-03-13 西格马-奥尔德里奇有限责任公司 产生内源标记的蛋白的方法
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
ES2754394T3 (es) * 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
MX341147B (es) * 2011-05-13 2016-08-09 Ganymed Pharmaceuticals Ag Anticuerpos para el tratamiento del cáncer que expresa cldn6.
SG11201404285VA (en) 2012-02-22 2014-10-30 Univ Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138576A1 (en) * 2007-03-16 2009-12-30 Kyowa Hakko Kirin Co., Ltd. Anti-claudin-4 antibody
CN102325885A (zh) * 2009-02-20 2012-01-18 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物

Also Published As

Publication number Publication date
JP2017518762A (ja) 2017-07-13
AU2019210582B2 (en) 2021-03-04
JP6726656B2 (ja) 2020-07-22
ES2717530T5 (es) 2022-05-06
RS58627B2 (sr) 2022-06-30
PL3126381T3 (pl) 2019-09-30
HRP20190472T1 (hr) 2019-06-14
WO2015150327A1 (en) 2015-10-08
AU2015239683A1 (en) 2016-09-08
JP7451858B2 (ja) 2024-03-19
EP3126381B1 (en) 2019-01-16
JP2020096630A (ja) 2020-06-25
AU2019210582A1 (en) 2019-08-22
MX376026B (es) 2025-03-07
US20170015720A1 (en) 2017-01-19
CA2942459C (en) 2023-03-07
EP3514172B1 (en) 2020-03-11
PL3514172T3 (pl) 2020-07-27
US20190389920A1 (en) 2019-12-26
DK3708579T3 (da) 2024-07-22
EP3126381A1 (en) 2017-02-08
FI3708579T3 (fi) 2024-07-16
US11345731B2 (en) 2022-05-31
EP3708579A1 (en) 2020-09-16
AU2021203528B2 (en) 2022-10-13
PL3708579T3 (pl) 2024-08-05
EP3126381B2 (en) 2022-02-16
MX2016012713A (es) 2018-03-01
JP6985440B2 (ja) 2021-12-22
RS65784B1 (sr) 2024-08-30
ES2784537T3 (es) 2020-09-28
HUE067504T2 (hu) 2024-10-28
HRP20190472T4 (hr) 2022-06-24
PL3126381T5 (pl) 2022-05-23
DK3126381T4 (da) 2022-04-04
PT3126381T (pt) 2019-04-18
ME03407B (me) 2020-01-20
AU2021203528A1 (en) 2021-07-01
BR112016022727A2 (pt) 2017-10-31
SI3514172T1 (sl) 2020-07-31
US20220306711A1 (en) 2022-09-29
ES2982838T3 (es) 2024-10-17
LT3126381T (lt) 2019-05-27
HUE050355T2 (hu) 2020-12-28
PT3514172T (pt) 2020-04-21
RS58627B1 (sr) 2019-05-31
SMT201900262T1 (it) 2019-07-11
BR112016022727A8 (pt) 2018-12-04
SI3126381T2 (sl) 2022-05-31
NZ723544A (en) 2021-10-29
CY1121539T1 (el) 2020-05-29
US10370423B2 (en) 2019-08-06
DK3514172T3 (da) 2020-04-06
CN106459165A (zh) 2017-02-22
JP2022046462A (ja) 2022-03-23
CN113150110A (zh) 2021-07-23
PT3708579T (pt) 2024-07-17
CA2942459A1 (en) 2015-10-08
ES2717530T3 (es) 2019-06-21
SI3708579T1 (sl) 2024-09-30
HRP20240926T1 (hr) 2024-10-11
AU2015239683B2 (en) 2019-08-22
HUE044515T2 (hu) 2019-10-28
EP3514172A1 (en) 2019-07-24
EP3708579B1 (en) 2024-05-01
CN113150109A (zh) 2021-07-23
LT3708579T (lt) 2024-07-25
SI3126381T1 (sl) 2019-07-31
DK3126381T3 (en) 2019-04-15

Similar Documents

Publication Publication Date Title
JP7451858B2 (ja) クローディン６特異的免疫受容体およびｔ細胞エピトープ
US20230303656A1 (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
HK40055485A (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK40048260A (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK40080457A (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
HK40026429B (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK40026429A (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK40011474B (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK40011474A (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK1247815B (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
HK1250331B (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
HK1246802A1 (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK1246802B (en) Claudin-6-specific immunoreceptors and t cell epitopes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20170418

Address after: The German city of Mainz

Applicant after: Byrne Technology Cell & Gene Therapy Co.,Ltd.

Applicant after: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GE

Applicant after: GANYMED PHARMACEUTICALS AG

Address before: The German city of Mainz

Applicant before: Byrne Technology Cell & Gene Therapy Co.,Ltd.

Applicant before: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GE

Applicant before: UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNI MAINZ

Applicant before: GANYMED PHARMACEUTICALS AG

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Mainz, Germany

Patentee after: Byrne Technology Cell & Gene Therapy Co.,Ltd.

Country or region after: Germany

Patentee after: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GE

Country or region after: De Guo

Patentee after: Ganimead Pharmaceutical Co.,Ltd.

Address before: Mainz, Germany

Patentee before: Byrne Technology Cell & Gene Therapy Co.,Ltd.

Country or region before: Germany

Patentee before: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GE

Country or region before: De Guo

Patentee before: GANYMED PHARMACEUTICALS AG

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240222

Address after: Mainz, Germany

Patentee after: Byrne Technology Cell & Gene Therapy Co.,Ltd.

Country or region after: Germany

Patentee after: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GE

Patentee after: ASTELLAS PHARMA Inc.

Country or region after: Japan

Address before: Mainz, Germany

Patentee before: Byrne Technology Cell & Gene Therapy Co.,Ltd.

Country or region before: Germany

Patentee before: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GE

Country or region before: De Guo

Patentee before: Ganimead Pharmaceutical Co.,Ltd.